The Framingham Heart Study (FHS) is one of the world’s most informative and longest-running studies
73 Mount Wayte Avenue Ste 2
Framingham, MA
01702
| Monday | 9am - 3pm |
| Tuesday | 9am - 3pm |
| Wednesday | 9am - 3pm |
| Thursday | 9am - 3pm |
| Friday | 9am - 3pm |
Be the first to know and let us send you an email when Framingham Heart Study posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Framingham Heart Study:
The Framingham Heart Study (FHS) is one of the world's most regarded research studies, starting first with its work on heart disease and expanding to other chronic diseases such as stroke, cancer, osteoporosis, diabetes and Alzheimer's disease. With over 3,700 articles published in academic journals such as the New England Journal of Medicine, the Journal of the American Medical Association, Nature Genetics, Circulation and the Lancet, FHS now seeks to do more. Fueled by the extraordinary dedication of three generations of participants, Framingham’s expansion into genomics, transcriptomics, and proteomics coupled with on-going integration of state-of-the-art technology, reflects its continued pursuit of new and innovative research. Framingham is credited with much of the earliest findings that smoking, high blood pressure, high cholesterol, obesity, and diabetes lead to heart disease. In coining the term "risk factor" in 1961, the study set the foundation for the field of preventive medicine. Today, the study remains a global epicenter for public health research, operating at the intersection of population research, omics, systems biology, and personalized medicine. The Framingham Heart Study is a project of Boston University and the National Heart Lung and Blood Institute.
The Framingham Heart Study is supported by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health and Boston University School of Medicine, under NIH award 75N92019D00031.
